These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38686708)

  • 21. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
    Guo Y; Chu X; Parrott NJ; Brouwer KLR; Hsu V; Nagar S; Matsson P; Sharma P; Snoeys J; Sugiyama Y; Tatosian D; Unadkat JD; Huang SM; Galetin A;
    Clin Pharmacol Ther; 2018 Nov; 104(5):865-889. PubMed ID: 30059145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
    Samineni D; Ding H; Ma F; Shi R; Lu D; Miles D; Mao J; Li C; Jin J; Wright M; Girish S; Chen Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S120-S131. PubMed ID: 33205435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
    Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations.
    Ke AB; Greupink R; Abduljalil K
    CPT Pharmacometrics Syst Pharmacol; 2018 Feb; 7(2):103-110. PubMed ID: 29349870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles.
    Li M; Zou P; Tyner K; Lee S
    AAPS J; 2017 Jan; 19(1):26-42. PubMed ID: 27834047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States.
    Sharma S; Suresh Ahire D; Prasad B
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric Dose Selection and Utility of PBPK in Determining Dose.
    Templeton IE; Jones NS; Musib L
    AAPS J; 2018 Feb; 20(2):31. PubMed ID: 29441439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.
    Pan Y; Hsu V; Grimstein M; Zhang L; Arya V; Sinha V; Grillo JA; Zhao P
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S122-31. PubMed ID: 27385170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.